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EXPLJ\NATION OF THESIS FORMAT 
The following thesis consists of a general introduction, a review of 
the literature, two separate manuscripts (Sections I and II), a general 
summary, literature cited, and acknowledgements. The master's candidate, 
Michael James Mc Ginley, is the senior author and principal investigator 
for each of the manuscripts. 
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GENERAL INTRODUCTION 
Pseudorabies virus (PRV) causes an economically important disease of 
swine that is generally controlled by vaccination. While vaccination 
with currently available modified live or killed commercial vaccines 
provides adequate protection from disease the differentiation of 
vaccinated pigs and virus infected pigs is not possible. Consequently, 
vaccinated pigs must be labelled as latent carriers and potential 
disseminators of PRV. The use of PRV subunit vaccines with a defined 
antigenic composition makes differentiation possible by utilizing non-
vaccine component PRV proteins as diagnostic antigens. As a result, 
subunit vaccines and associated diagnostic antigens can greatly aid in 
the control and possible eradication of PRV from the swine population. 
Subunit vaccinated pigs will be exposed to minimum infective doses 
of PRV under field conditions. Consequently, the host immune response 
may suppress virus infection before sufficient al!Dunts of PRV diagnostic 
antigen are produced. This may result in an undetectable antibody 
response to the diagnostic antigen in latently infected subunit 
vaccinated pigs. In the following study the ability of low doses of 
pseudorabies virus (PRV) to induce detectable antibody levels to a 98K 
diagnostic antigen (DA) and to establish latency in subunit vaccinated 
pigs was investigated. In addition, the efficacy of PRV nucleocapsid 
proteins as diagnostic antigens was evaluated under similar PRV exposure 
conditions. 
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LITERATURE J;IBVIEW 
Introduction 
Pseudorabies (Aujeszky's disease) is an e=nomically inportant 
disease of swine caused by the pseudorabies virus (PRV), a member of the 
family Herpesviridae. 28 Since its initial description in 1902 by the 
Hungarian veterinarian Aladar Aujeszky3 the worldwide incidence and 
e=nomic impact of pseudorabies have increased.lOl Slaughter survey sera 
from the U.S. indicated 0.56% of pigs were positive for PRV in 1974. 22 
This figure rose to 3.73% in 1978 and 8.39% in 1981. 91 E=nomic losses 
to the Iowa swine industry alone were estimated at $33.9 million in 
1981.13 A 1985 study, taking into account losses due to PRV infection 
of breeding stock, estimated the economic loss in Iowa to be $107 to $117 
million per annum. 30 
The =ntrol of pseudorabies can be ac=rnplished by the elimination 
of infected pigs from the herd or by vaccination to prevent the spread of 
virus within the herd. 91 In both cases distinguishing PRV infected pigs 
from PRV vaccinated pigs is of primary inportance. A major limitation of 
currently available modified live or killed =mmercial vaccines64,90,94 
is that vaccinated pigs cannot be differentiated from virus infected 
carrier pigs. 44 The use of subunit vaccines with limited and defined 
antigenic =nposition in =njunction with a non-vaccine diagnostic 
antigen makes this distinction possible. This concept has been 
demonstrated in PRV subunit vaccinated pigs using an early PRV specific 
excreted protein not present the vaccine preparation.70 The following 
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review of the literature will concentrate on the pseudorabies virus and 
its protein COl![Xlsition, the concept of subunit vaccines, and a general 
description of what is known about the porcine innnune response to 
pseudorabies virus. 
Pseudorabies Virus 
Pseudorabies virus (suid herpesvirus I) is a member of the family 
Herpesviridae. 78 .The virus has been further classified into the 
subfamily alpha herpesvirinae based on its wide host range, short 
replication cycle, rapid cytopathic effect leading to cell death, and its 
ability to establish latent infections.1•25•58•78•79•80 Representative 
members of the alpha herpesvirinae related to pseudorabies virus include 
herpes simplex virus types 1 and 2, equine herpesvirus type 1, and bovine 
herpesvirus type 1 and 2.26,38,43,78 
Pseudorabies virus has an icosahedron capsid symmetry of 162 
capsomeres with an approximate average diameter of 180 nm as measured by 
phosphotungstic negative staining and electron microscopy.9,42,82 The 
capsid surrounds a double-stranded DNA genome with a molecular weight of 
90 x 106 daltons. 9 The genome consists of four distinct regions; a 
unique long region (UL) of 65 x 106 daltons, an inverted repeat region 
(IR) and terminal repeat region (TR) of 10 x 106 daltons each, and a 
unique short region (US) of 6 x 106 daltons located between the IR and 
the TR regions. 9•11•89 The nucleocapsid (capsid and genome) is 
surrounded by an envelope consisting of a double or triple lipid-
containing membrane rich in glycoproteins which is derived from the 
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nuclear or cytoplasmic membrane of virus infected cells.8121•75 
Pseudorabies Virus Proteins 
The number of polypeptides identified from purified PRV preparations 
has changed over time with advances in separation techniques and improved 
resolution.9 Original estimates indicated approximately 10 polypeptides 
were associated with purified virions. 7 SUbsequent studies have 
identified a minimum of 20 and as many as 27 polypeptides in purified PRV 
preparations. 9•66•68•88 Several structural proteins have been 
identified: four of these are phosphoproteins9 and four major and three 
minor structural proteins are glycosylated.9,32,53 In addition, several 
non-structural viral proteins have been identified.23,40,69,70,73,93 The 
following review of pseudorabies virus proteins will focus on the 
structural proteins associated with the virus envelope and nucleocapsid 
as well as the non-structural virus-directed proteins. 
Pseudorabies virus envelope proteins 
The PRV envelope fraction contains approximately 50% of the virus 
protein and all of the glycoproteins. 32•39 The virus envelope has been 
shown to contain four major and three minor structural glycoproteins as 
well as one non-glycosylated protein. 32 A proposed nomenclature for the 
pseudorabies virus envelope proteins32 is summarized in Table 1. 
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Table 1. The envelope proteins of pseudorabies virus 
Major glycoproteins 
12~ 
98K 
74Ka 
(g!Ia) 
(gIII) 
(g!Ib) 
5~ (gIIc) 
Nonglycosylated protein 
llSK 
Minor glycoproteins 
(gI) 
(gIV) 
(gV) 
~ese three major glycoproteins are covalently linked by 
disulfide bridges. 
bThe three minor glycoproteins are noncovalently linked and form 
a corrq;>lex with the llSK nonglycosylated protein. 
The four major envelope glycoproteins are highly sulfated and have 
molecular weights of 125K (gIIa), 98K (gIII), 74K (gIIb), and 58K 
(gIIc). 23• 32•47 Analysis of detergent extracted virus envelopes by 
radioinununoprecipitation with monoclonal antibodies reactive to envelope 
fractions has shown that the 125K, 74K, and 58K glycoproteins reside as a 
corrq;>lex covalently linked by disulfide bridges.32 Partial peptide 
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mapping of these three glycoproteins shows extensive sequence homology 
indicating that the individual peptides may have originated from a single 
precursor protein.32,47,53 The fourth major glycoprotein (98K, gIII) is 
not corrplexed to any other protein. 32 The three minor envelope 
glycoproteins with molecular weights of 130K (gI), 98K (gIV), and 62K 
(gV) form a noncovalently linked corrplex with a 115K non-glycosylated 
protein.32,47,53 
Because the envelope glycoproteins are on the surface of the virion, 
they probably play a primary role in eliciting a host immune 
response. 32•84•98 Monoclonal antibody studies have denonstrated that 
antibody to. the major 98K (gIII) glycoprotein will inhibit virus 
absorption and neutralize virus infectivity in the absence of 
corrplement.32 Wathen et al. demonstrated that the 58K (gIIc) protein may 
also induce serum-virus neutralizing antibody. 97 Similar studi~s 
indicate antibody directed to the other envelope glycoproteins have 
little serum-virus neutralizing activity.9,32 The possible role of 
these envelope proteins in inducing cell-mediated immune responses has 
not been investigated to date. 
Pseudorabies virus nucleocapsid proteins 
Viral nucleocapsids consist of nucleic acid and associated proteins 
surrounded by a protein capsid. 25 •50 Early studies on the protein 
corrposition of PrV nucleocapsids described three major proteins with 
molecular weights of 142K, 35K, and 32K and a minor protein with a 
molecular weight of 62K. 8•39 Subsequent studies by Stevely identified a 
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total of eight nucleocapsid proteins. 88 Four of these were in close 
agreement with earlier studies. In addition, four minor proteins with 
molecular weights of 120K, 82K, 41K, and 22.SK were resolved. 88 
Pseudorabies virus non-structural proteins 
A recent review by Ben-Porat and Kaplan9 summarizes the information 
available to date on the character and function of PRV specific non-
structural proteins and organizes them into four general categories: 
immediate early (IE) protein, DNA-binding proteins, virus.enzymes, and 
excreted glycoproteins. 
The IE protein of PRV is a multifunctional, !SOK protein that 
appears to regulate several processes in PRV infected cells.9,34 The IE 
protein has been shown to be a requirement for orderly PRV RNA 
transcription34 and in fact acts as a repressor of IE mRNA 
transcription.24 In addition, the IE protein contributes to the 
disruption of cellular mRNA-ribcsome COIIq?lexes which in turn inhibits 
cellular protein synthesis.10,11,34 
To date, at least 16 DNA-binding proteins specified by PRV have been 
described. 9 These DNA-binding proteins include beth structural and non-
structural proteins. Two major non-structural DNA-binding proteins with 
molecular weights of 136K and lSK have been described in detail.9 The 
major 136K DNA-binding protein synthesized by PRV is responsible for 
initiating the first round of virus DNA synthesis and later rounds of 
virus DNA replication, as well as stabilizing progeny virus DNA,9,12 The 
lSK DNA-binding protein is found in association with the large 
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concatameric PRV DNA (polymerized copies of PRV the genome) found in 
infected cells late in the infection.9 The !SK protein appears to 
function in the stabilization of the DNA. 9 The reJOC>val of the lSK 
protein and a closely associated !OK structural protein from concatameiic 
DNA by isopycnic centrifugation in cesium chloride results in double~ 
stranded breaks in the viral DNA.9 
A limited number of PRV specific enzymes have been described to 
date. 9 Those that have been described are thymidine kinase (TK), PRV-
induced DNA polymerase, and a PRV-induced DNase. 9 The PRV TK enzyme 
generates the DNA precursor deoxythymidylate (dTMP) from free 
thymidine.41,99 The PRV TK provides a thymidine utilization pathway 
independent of the cellular thymidilate synthetase pathway.SS The PRV-
induced DNA polymerase i~ antigenically distinct from cellular DNA 
polymerase and provides PRV with a cell independent DNA polymerase. 31 
The PRV-induced DNase is an exonuclease that catalyzes the release of 
deoxyribonucleoside-S'-JOC>nophosphates from the 3' end of DNA and is also 
antigenically distinct from cellular DNase.9,42 
The primary non-structural protein of PRV is a highly sulfated 
excreted glycoprotein that is produced and accumulates in large 
quantities in the medium of PRV infected cells. 23•40169, 7o, 73,93 Kaplan 
and Ben-Porat described this protein as a highly sulfated protein with a 
JOC>lecular weight of 90K. 40 Later studies by Platt described a similar 
protein with a JOC>lecular weight of llOK that could be used to detect 
virus infection in PRV subunit vaccinated pigs.69,70 In a subsequent 
study, Rea et al. mapped and sequenced a gene coding for a 9SK 
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gly=protein. 73 Rea et al. named this protein gX and it appears to be 
identical to the highly sulfated excreted gly=protein described 
previously. 40 Recent work by ThOlllSen et al. denonstrated that gX did 
not induce PRV neutralizing antibody raised in animals.93 The same 
investigator =ncluded from studies with gX""" mutants that the protein was 
not directly associated with virulence or virus replication.93 Although 
a specific function has not been associated with gX, it has been 
hypothesized that it may serve as a "scaffolding protein" involved in 
intracellular virion assemb1y23 or it may aid in viral evasion of host 
immune responses by pronoting cell fusion.20,62 
Subunit Vaccines 
Subunit vaccines are defined as vaccines =ntaining only those viral 
structures necessary for the induction of a protective host illUllune 
response. 49•74•83 General methods for the production of these subunit 
vaccines include the extraction of specific proteins from whole virion 
preparations, 56 extraction of virus infected cell membranes,69,77,95 
viral peptide synthesis, 16 and various applications of re=mbinant DNA 
technology.14,16,45, 46, 51•76 The absence of whole virus and viral 
nucleic acid in subunit vaccines makes them safer than attenuated or 
inactivated vaccines because they are: non-infective,19,74,83 less 
toxic, 81 and incapable of establishing latent infections.74,83 These 
qualities make it possible to administer large doses of immunogen from 
virulent virus without adverse effects intrinsic to traditional vaccines. 
Additionally, the limited antigenic =rnposition of subunit vaccines makes 
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it possible to identify virus infected subunit vaccinated animals by 
serologically testing for antibody to non-vaccine viral components. 
Subunit vaccine preparations have been evaluated with respect to a number 
of herpesviruses such as; infectious bovine rhinotracheitis (IBR), 54 
equine herpesvirus type 1 (EHV-1), 64 Marek's disease 
virus,35,36,37,52,102 herpes simplex virus type 1 (HSV-l),15,48,72,87,103 
herpes simplex virus type 2 (HSV-2), 86•96 and pseudorabies virus 
(PRV).68,69,70,77,95 
Initial PRV subunit vaccine preparations consisted of detergent 
extracts of viral envelope glycoproteins. 56168177195 The use of non-
ionic detergents such as Triton X-100 (TX-100) and Nonidet P-40 for 
protein extraction was initially employed in the isolation of membrane 
bound cell receptors, transplantation antigens, and histocompatability 
antigens. 33•55 The technique was subsequently adapted for use in the 
extraction of protective inmrunogens4•18•20•27 from the envelopes of whole 
virions56 and/or virus infected cell membranes.65,68, 77,95 In 1980, Rock 
and Reed first evaluated a TX-100 extract of PRV infected cells and found 
the extracted viral antigens to be highly inmrunogenic and protective in 
mice. 77 This finding was confirmed in 1981 by Turner et al. with a 
similar NP-40 detergent extract. 95 A similar study by Maes and Schutz 
showed NP-40 extracts of intact virion induced inmrunity in swine.56 They 
also reported that this inmrunizing preparation stimulated the production 
of higher levels of neutralizing antibody than either attenuated or 
inactivated vaccines. 56 In 1982, Platt denonstrated that the 
administration of TX-100 extracts of PRV infected cells induced PRV 
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specific protective immunity in swine. 69 Subsequently, Platt showed that 
the glycoproteins isolated from crude detergent extracts by lectin 
affinity chromatography also induce protective immunity. 69 He also 
demonstrated that pigs which were immunized with lectin purified 
preparations did not have antibody to a PRV-specific early excreted non-
structural protein. 69 These findings led to the successful use of the 
early excreted protein as a diagnostic antigen to identify virus infected 
vaccinated pigs. 70 
The Porcine Immune Response to PRV. 
The humeral immune response to PRV is generally characterized by 
serum virus-neutralizing antibody (SN) assays. I.ow levels of IgM class 
SN antibody are detectable 7 to 10 days post-infection (p.i.).29,57,59,67 
Serum IgM titers peak at day 10 p.i. and are generally detectable until 
day 14 p. i. at which time they dramatically decrease. 57 Meanwhile, IgG 
titers increase dramatically to day 14 p.i. and generally peak by day 35 
p.i. 57•60 Serum virus-neutralizing antibody is primarily responsible 
for neutralizing free virus in blood and tissue fluids.5 
The role of local secretory immunity is linked to the fact that the 
primary route of PRV natural infection is via the mucosa of the 
nasopharynx. 6 Therefore, IgA class antibody in nasal secretions is an 
important aspect of humeral immunity. 6 The anti-PRV IgA response after 
initial infection is generally brief. 5 Shortly after infection low 
levels of antibody remain on the mucosal surfaces.5 Havever, re-exposure 
to PRV results in the induction of high levels of protective anti-PRV 
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IgA.5,6 The specific aspects relating to the induction of primary 
secretory i=nity and subsequent menvry have not been described in the 
pig. 
The initial low levels and late onset of hunvral innnune responses 
have led some investigators to believe that cell-mediated i=nity is the 
primary i=ne response in the early stages of PRV infection. Cell-
mediated i=nity (CM!) in response to PRV and other herpesvirus 
infections has been denvnstrated by the following methods: lymphocyte 
transformation,100,101 macrophage migration inhibition, 5 delayed 
hypersensitivity skin reaction, 5 antibody-dependent cell-mediated 
cytotoxicity, 2 and specific MliC-directed cytotoxic T-lymphocyte 
killing.81 
Wittmann et al. denvnstrated the early onset of CM! by stimulating 
the transformation of lymphocytes collected from regional lymph nodes and 
spleen at 4 days p.i. Serum-virus neutralizing antibody was not detected 
until day 7 p. i.101 In addition, Ashworth et al. detected anti-PRV CM! 
by antibody-dependent cell-mediated cytotoxicity (Arx:::C) in 50% of non-
i=ne pigs exposed to virus on day 7 p. i. when no SN antibody was 
detectable and in all pigs when SN antibody titers were uniformly low. 2 
This study ill!J?lies that non-detectable levels of antibody may participate 
in early cell-mediated killing of PRV infected cells. 2 Denvnstrations of 
MliC specific T-cytotoxic killing in response to PRV infection are not 
available. However, extensive studies of closely related herpes sill!J?lex 
virus (HSV) types 1 and 2 in mice have shown that cytotoxic T-lymphocytes 
specifically lyse HSV infected syngeneic cell cultures. 81 These studies 
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indicated cytotoxic T-lynphocytes play a significant role in recovery 
from infection. 81 Other studies indicate that lynphocytes bearing T-
helper and delayed hypersensitivity narkers also play a significant role 
in recovery from HSV infection. 63 
The humeral immune response of pigs following vaccination is in 
general similar to that observed in natural infection. Typically, low 
levels of PRV specific SN antibody are detected following inoculation 
with PRV modified live61 or subunit vaccines69 ; however, exposure of 
vaccinates to virus results in a marked anamnestic SN antibody 
response. 61•69 The extent of local secretory and cell-mediated immunity 
induced by vaccination has not been investigated to date: 
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SECI'ION I. PSEUOORABIES VIRUS SUBUNIT DIAGNOSTIC ANI'IGENS MAY FAIL TO 
DEI'ECT IATENT INFECTIONS INDUCED BY LaV VIRUS EXPOSURE DOSES 
This manuscript has been submitted for publication to the American 
Journal of Veterinary Research. 
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SUMMARY 
The ability of low doses of pseudorabies virus (PRV) to induce 
detectable antibody levels to a 98K diagnostic antigen (DA) and to 
establish latent infections in subunit vaccinated pigs was studied. The 
relationship of virus exposure dose and vaccine dose to the response of 
pigs to DA was studied in 18 pigs. Two groups of three pigs were 
inununized with a total of 200ug of a lectin derived PRV subunit vaccine 
over a five week period. Two additional groups of three pigs were 
similarly inununized with a total of lOOug. Two groups of three pigs 
served as uninoculated controls. One group of pigs from each of the 
preceding categories was intranasally challenged with 106.0 and 102.7 PFU 
of virus. Antibody to DA was detected by enzyme-linked inununosorbant 
assay (ELISA) and radioimmunoprecipitation (RIP) three to seven days 
earlier in both vaccine groups that were challenged with 106•0 PFU. 
These results demonstrate that virus challenge dose affects the antibody 
response to DA. 
The establishment of latent infections by low PRV exposure doses and 
the ability to detect these infections was studied in 10 subunit 
vaccinated pigs. EaCh pig was intranasally challenged with 102•3 PFU of 
virus. The serum-virus neutralizing (SN) antibody titer of these pigs 
rose to a peak at 14 to 21 days post challenge (p.c.) and then steadily 
declined through day 113 p.c. indicating an absence of viral 
recrudescence. All.pigs were treated with dexamethasone for four 
consecutive days beginning on day 113 p.c. Latent infections were 
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identified in eight of 10 pigs (80%) based on the recovery of virus 
and/or two log2 or greater increases in SN titer. Antibody to DA was 
detected in the eight latently infected pigs for periods ranging from 21 
to 113 days p.c. before dexamethasone treatment. The antibody titer to 
DA. increased in six of the eight latently infected pigs following 
dexamethasone treatment. However, no antilxxly to DA was detected in the 
remaining two latently infected pigs (25%) despite significant increases 
in SN titers and the re=very of reactivated virus in one of the pigs. 
The failure to consistently detect antibody to 98K DA in latently 
infected pigs demonstrates that the reliability of diagnostic tests that 
use non-vaccine diagnostic antigen may only be suitable for detecting 
infections in vaccinated herds and not in individual pigs. 
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INTRODUCTION 
Subunit vaccines may prove to be valuable tools in pseudorabies 
virus (PRV) control programs. These vaccines will not only provide 
protection from clinical disease and slow the spread of virus within a 
herd but because of their limited antigenic conposition they will offer 
the unique advantage of permitting the detection of virus infection in 
vaccinated pigs. The ability to detect virus infection in subunit 
vaccinated pigs has been previously documented in earlier work in which 
an early excreted non-vaccine viral protein was used as a diagnostic 
antigen. 9 The virus challenge doses used in these experiments were 107·4 
PFU and greater. Under field conditions the virus exposure doses in 
vaccinated herds will most likely be lower and possibly approach the 
minimum infective dose since smaller amounts of virus are shed by 
vaccinated pigs than by non-vaccinated pigs.1,7 Consequently, it is 
conceivable that a virus infection may be suppressed by specific host 
immune responses before a sufficient amount of non-vaccine viral protein 
can be generated that will induce a detectable antibody response. Under 
these conditions subunit vaccinated pigs may remain seronegative to 
diagnostic antigen but be latently infected. The following study was 
undertaken to test this hypothesis. 
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MATERIALS AND MEI'HODS 
Virus, Cells, and Medium 
Pseudorabies virus (PRV) strain Bes was used for bJth viral antigen 
production and challenge virus. Madin Darby bJvine kidney (MDBK) cells 
were obtained from the National Veterinary Services laboratory, Ames, IA. 
Pig kidney la cells were obtained from the Veterinary Medical Research 
Institute, Iowa State University, Ames, IA. Growth medium consisted of 
Dulbecco' s modified Eagle's medium (D-MEM) supplemented with 10% fetal 
calf serum or 10% horse serum (GIBCO laboratories, Grand Island, NY). 
Subunit Vaccine and Diagnostic Antigen 
VaGcine preparation has been previously described. 7 Essentially, 
viral glycoproteins were extracted from solubilized PRV infected pig 
kidney cell membranes and isolated by lectin affinity chromatography 
using I.ens culnaris agglutinin covalently linked to agarose beads (E-Y 
Laboratories, San Mateo, CA). Bound glycoprotein was eluted with 2. 5% 
mannose in 0.025M Tris/Tricine (TT) buffer pH 8.4 and concentrated 10 
fold by ultra-filtration through a 30K nolecular weight cut-off membrane 
(Diaflo YM30.ultrafilter, Amicon Corporation, MA). The protein 
concentration of column eluate was determined by a dye binding method 
described by Bradford. 2 Column eluate was diluted to specific protein 
concentration in TT buffer and emulsified in an equal volume of Freund's 
incomplete adjuvant. 
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Diagnostic antigen (DA) was serum-free maintenance media of MDBK 
cells =llected 6h after PRV infection. This preparation was shown in an 
earlier study to contain high levels of relatively pure excreted PRV 
gly=protein. The rolecular weight of this protein was determined to be 
llOK by size exclusion high performance liquid chromatography, 9 106K by 
sodium deodecyl sulfate-polyacrylarnide gel electrophoresis (SI::s-PAGE), 
and 98K by sns-PAGE analysis of 35s methionine labelled 
irnmunoprecipitate. The physical and biochemical properties of DA 
closely resemble those described for the PRV protein gX.10,12 Normal 
host cell antigen (NB:C) was serum-free maintenance media =llected from 
identically treated normal MDBK cells. 
Serum Neutralization 
Serum neutralization (SN) titers were determined as previously 
described5•9 and are expressed as the reciprocal of log2. 
Enzyme-Linked Irnmunosorbent Assay 
Both DA and NBC were diluted in antigen coating buffer consisting of 
Q.02M sodium carbonate/bicarbonate buffer pH 9.6 =ntaining 1 mg/ml of 
water soluble carbodiimide l-ethyl-3-(-3-dimethylarninopropyl)carbodiimide 
(Sigma Chemical Corrpmy, St. I.Duis, MO) to enhance antigen binding.3 One 
hundred ul of each antigen preparation was incubated at 4°c for 16-24h in 
individual wells of polystyrene microplates (Irnrnulon I microplates, 
Dynatech I.abs Inc. , Alexandria, VA). Unadsorbed antigen was reroved by 
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washing all wells three times with O.OlM phosphate buffered saline, pH 
7,2 containing 0.5% Tween 20 (ELISA wash buffer). Unreacted sites were 
blocked by treating individual wells with 2.0% gelatin in antigen coating 
buffer for 2h at 37°C. Serums were diluted 1/20 in antibody/conjugate 
diluent consisting of o. 05M Tris, 150I!M sodium chloride, O. OlmM EDI'A, pH 
7.4 containing 0.05% Tween 20 and 1.0% gelatin and added at a rate of 
lOOul to individual wells coated with DA and NHC. Serum preparations 
were incubated at 37°c for 15 min, washed eight times with ELISA wash 
buffer and air dried for 10 min. Goat anti-porcine IgG (H+L) conjugated 
to horseradish peroxidase (Kirkegaard & Perry Laboratories Inc., 
Gaithersburg, MD) was diluted 1/3500 in antibody/conjugate diluent, added 
at a rate of lOOul/well and incubated at 37°C for 45 min. Plates were 
washed eight times with ELISA wash buffer as described above. One 
hundred ul of enzyme substrate that was prepared by adding 50 ul of a 30% 
concentrated solution of hydrogen peroxide and 20 mg of o-
phenylenediamine chromagen to 100 ml of 0.02M citric acid, pH 5.0, was 
added to individual wells and reacted in the dark at 25"c for 20 min. 
The resulting color reactions were stabilized with 4.5M sulfuric acid. 
Absorbance values were determined with an automatic microplate 
reader (Dynatech MR600 microplate reader, Dynatech Labs Inc.) with a test 
filter wavelength of 490 nm. Absorbance values of individual samples 
were determined by subtracting the optical density (O.D.) value of NHC 
from the O.D. value of DA and expressed as the mean of four replications. 
A baseline o.n. reaction was established using 40 known negative serums 
that gave a corrected o.n. range of o.ooo to 0.100. Corrected o.n. 
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values of 0.150 or greater were considered positive. Antibody titers 
were considered to be directly proportional to corrected O.D. values. 
Production of Radiolabelled Diagnostic Antigen 
The production of radiolabelled DA for immunoprecipitation was the 
same as the production of unlabelled DA with the following exceptions. 
Virus inoculum was diluted in D-MEM containing 2% horse serum. After 90 
min the inoculum was removed, the cell monolayer was washed three times 
with serum-free and methionine free D-MEM, and replaced with the same 
medium at the rate of 5 ml/150 cm2 flask. After lh the media was 
replaced with 5.0 ml of fresh serum free D-MEM containing 100 uci 
[35s]Methionine/m1 (Amersham Corporation, Arlington Heights, IL). At 6h 
p.i. the media was harvested, centrifuged at 100,000 x g for 90 min and 
stored in aliquots at -70°c until used. 
Sodium Deodecyl Sulfate-Polyacrylamide Gel Electrophoresis 
Sodium deodecyl sulfate-polyacrylamide gel electrophoresis was 
performed by standard methods. 4 Briefly, DA was diluted in an equal 
volume of sample preparation buffer consisting of 2% sodium deodecyl 
sulfate, 4% B-mercaptoethanol, 0.05% bromophenol blue and 50% glycerol in 
O.SM Tris pH 6.8. Stacking and separating gels consisted of 4 and 10% 
acrylamide monomer respectively, cross-linked with bis-acrylamide at a 
ratio of 30:0.8. All gels were electrophoresed at 25 mA until the 
samples reached the stacking gel/separating gel interface. Sample 
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separation was completed by electrophoresis at a constant current of 35 
mA. 
Radioinununoprecipitation 
Radioinununoprecipitation was performed as described by Wathen and 
Wathen. 13 Briefly, 100 ul of radiolabelled DA was combined with 25 ul of 
test serum. The mixture was gently vortexed, and incubated at 4°c for 
16-1811. The antigen-antibody complexes were harvested by adding 25 ul of 
a 40% vol/vol solution of freshly washed s.aureus protein A-sepharose 
beads (Sepharose CL-4B, Pharmacia Fine Chemicals, Piscataway, NJ). This 
preparation was incubated at 4°c for l h with periodic gentle agitation 
and the protein A beads were harvested by centrifugation for 2 min. The 
beads were washed six times with TI' buffer, boiled for 3 min in sample 
preparation buffer and analyzed by SDS-PAGE. Electrophoresed gels were 
impregnated with 2,5-diphenyloxazole scintillant in dimethyl sulfoxide, 
washed with deionized water, dried under vacuum and exposed to Xl\R5 film 
(Eastman Kodak Company, Rochester, NY) at -7o0 c for three to six days. 6 
Experimental Design 
Two studies were conducted. The first study was designed to 
characterize the effect of the level of inununity and virus exposure dose 
on the antibody response of pigs to diagnostic antigen (DA). The second 
study was designed to determine if latent infections could be established 
in subunit vaccinated pigs by low doses of virus without inducing 
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persistent antil:xxly titers to DA. 
Sixteen pigs were used in the first study. Two groups of six pigs 
each were inoculated subcutaneously twice at 21 day intervals with 100 
and 50 ug of antigen respectively. A third group of four pigs served as 
non-vaccinated controls. All three groups were equally divided, 
separately housed and nasally challenged with 2.0 ml of virus suspension 
containing 106.0 or 102.7 PFU of virulent PRV 21 days after the second 
vaccine dose. Serum was collected on both days of inoculation, 10 days 
before virus challenge, the day of challenge, and on days 4, 7, 10, 14, 
and 21 days p.c. Serums from each group were pooled by day and analyzed 
for antil:xxly to DA by ELISA and RIP. Serum virus neutralization titers 
were determined for individual serums. 
The virus latency study was conducted with 16 pigs. Ten of these 
pigs were inoculated s.c. with one lOOug and two 50ug doses of vaccine 
antigen. Vaccinates and six non-vaccinated controls were separated 21 
days after the third vaccin~ dose and nasally challenged with 102·3 PFU 
of PRV in two ml of maintenance medium. Nasal swabs were collected prior 
to challenge and on days one through four p.c. and assayed for the 
presence of virus. Serums were collected on days O, 4, 7, 10, 14, and 21 
p.c. and assayed individually for virus neutralizing activity and 
antibody to DA. 
Challenged vaccinates were subsequently divided into three housing 
groups of three to four pigs each and 1113.intained through day 113 p.c. 
During this period SN titers of individual pigs continuously declined 
indicating the absence of spontaneous viral recrudescence. All 
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vaccinates were checked for latent infections on day 113 p.c. by 
injecting them with four daily doses of dexamethasone given i.p. at the 
rate of 1.5 mg/kg body weight. Previous studies derronstrated that 
similar doses of dexamethasone successfully reactivated latent PRV 
infections.11,14 Nasal swabs were collected prior to treatment and on 
days one through six post-treatment (p.t.) and assayed for virus 
activity. Serums were collected on days 0, 10, 14, 21, and 28 p.t. and 
individually assayed for neutralizing and DA antib:Jdy. Pigs were 
considered to have been latently infected if virus was recovered and/or a 
two log2 or greater rise in SN titer occured following dexamethasone 
treatment. 
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RESULTS 
The Effect of PRV Exposure Dose on the Antil:xxly Response to Diagnostic 
Antigen (DA) 
The effect of virus exposure dose on the antiJ:xx1y response to DA is 
sununarized in Figures 1 and 2. Enzyme-linked irnmunosorbant assay and RIP 
data clearly demonstrate that virus exposure dose influences the time of 
appearance and the relative level of the antiJ:xx1y response to DA in 
subunit vaccinated pigs. No antiJ:xx1y to DA was detected in either 
vaccine group by ELISA or RIP on the day of virus challenge. 
Subsequently, antiJ:xx1y to DA was first detected by ELISA on days 7 and 10 
in the low and high vaccine dose groups respectively and by RIP on day 7 
following nasal challenge with 106.0 PFU of virus. In contrast, antiJ:xx1y 
to DA was not detected by either ELISA or RIP until day 14 after exposure 
to 102• 7 PEU. 
AntiJ:xx1y to DA was detected earlier in the high vaccine dose group 
than in either the ~ow vaccine dose group or non-vaccinated controls 
following challenge with 106•0 PEU virus. AntiJ:xx1y to DA was also 
detected earlier in l::oth vaccine dose groups than in controls after 
challenge with 102•7 PEU virus. These results were unexpected and 
suggest that the subunit vaccine may have sensitized these pigs to DA. 
Figure 1. Radioinununoprecipitation detection of post-challenge antibody responses to 
[ 35s]Methionine-labelled diagnostic antigen in pooled serum collected from 
subunit vaccinated pigs. For all vaccine/challenge combinations n=3: Vaccine 
Il:lse I= 2xl00ug doses: vaccine Il:lse II= 2x50ug doses: High Challenge= 
106•0 PFU of pseudorabies virus (PRV): !JJw Challenge= 102"7 PFU of PRV: -C= 
normal negative pre-vaccination pig serum: -tC= PRVhyperinunune pig serum. 
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Two log2 or greater increases in SN titer preceded detection of DA 
specific antibody by four days following virus challenge with 102•7 PFU 
(Figures 2 . and 3) . In contrast antibody to DA was detected 4 days before 
increases in SN titer when vaccinates and controls were challenged with 
106.0 PFU (Figures 2 and 3). 
The Response of IJIUllUnized Pigs to Challenge with a Low Dose of Virus 
The SN antibody response of iJIUllUnized pigs following challenge with 
a low dose of virus is summarized in Figure 4. The group mean SN titer 
on day O was 2.s +o.2. This titer rose to a maximum of 6.3 :f:0·4 on day 
14 p.c. and steadily declined thereafter to a mean value of 3.5 :f:0.3 by 
day .113 p.c. when dexamethasone treatment was initiated. The SN response 
of individual pigs followed the same general pattern as the mean group 
response. The absence of periodic increases in SN titer indicated that 
virus recrudescence did not occur prior to dexamethasone treatment. 
Antibody responses to Ill\. are swmnarized in Figure 5. No antibody to 
DA was detected by ELISA on the day of challenge with 102 • 3 PFU of virus. 
Antibody to DA was initially detected by ELISA on day 14 p.c. in eight of 
10 pigs. No virus was recovered from nasal swabs during this period. 
The two remaining pigs seroconverted on day 21 p.c. while one 
seropositive pig from day 14 became seronegative and remained so through 
day 113 p.c. 
, Figure 3. Serum neutralizing antibody responses of individual 
subunit vaccinated and non-vaccinated pigs following 
pseudorabies virus (PRV) challenge. For all vaccine/ 
challenge combinations n=3; n=2 for control groups 
except that n=l for the control group exposed to 106•0 
PFU of pseudorabies virus (PRV) after day 10 p.c.; 
Vaccine D:>se I= 2xl00ug doses; Vaccine D:>se II= 2x50ug 
doses; day -63= day of initial vaccine inoculation; C= 
day of PRV challenge. 
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Figure 4. Serum neutralizing antibody response of subunit vaccinated pigs (n=lO) after exposure 
to 102 • 3 PFU of pseudorabies virus (PRV) and subsequent dexamethasone treatment. C= 
day of PRV challenge; D= day of initial dexamethasone treatment. 
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Antibody to DA continued to be detected. through day 113 p.c. in three of 
10 pigs and until days 21, 46, 53, and 110 p.c. in one, two, one, and two 
pigs respectively. 
The same general pattern of antibody response was revealed by RIP. 
Antibody to DA was initially detected in all 10 pigs by day 14 p.c. and 
continued to be detected through day 113 p.c. in five pigs and through 
days 46, 96, and 110 p.c. in one, two and two pigs respectively. 
Eight of .the 10 pigs were considered to have been latently infected 
based on increases in SN titer of two log2 units within the first 10 days 
after dexamethasone treatment and virus recovery from six of the eight 
pigs between days one and three p.t. The amount of. virus recovered from 
these six pigs ranged from 101.0 to 102.0 PFU. Antibody levels to DA as 
demonstrated by the intensity of the ELISA reactions also rose 
concurrently with the SN titer in six of eight latently infected pigs 
(Figure 5). Failure to detect increases in DA antibody by ELISA in the 
two remaining latently infected pigs was unexpected since virus was 
recovered and SN titers rose in both pigs after dexamethasone treatment. 
Hao/ever, an increase in DA antibody apparently did oc= in one of these 
pigs because RIP detected antibody after but not inunediately before 
treatment. 
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DISCUSSION 
The preceding study has clearly denonstrated that latent infections 
can be readily established in subunit vaccinated pigs that are exposed to 
low doses of virus. Furthernore, the ability to identify these 
infections by assaying for antil:xldy to a non-vaccine early excreted 98K 
PRV protein using ELISA was variable. Only four of eight latently 
infected pigs had detectable DA antil:xldy 110 days after challenge. 
Antil:xldy to DA was detected in the remaining pigs for periods ranging 
from 14 to 53 days p.c. The variability of this response to DA may have 
been due to the ability of the immunized pigs to suppress virus 
replication which in turn limited the anount of DA that was produced in 
the host. This explanation may also account for the failure of two 
latently infected pigs to produce ELISA detectable DA antibodies 
following viral recrudescence. This hypothesis is supported by the fact 
that a direct relationship exists between virus challenge dose and DA 
antibody response in both subunit vaccinate and non-vaccinated controls 
(Figure 1). 
The variable nature of the antil:xldy response of immunized pigs to 
' the 98K DA that was observed in the above study is in direct contrast to 
earlier work in which all similarly immunized pigs responded to high 
doses of virus.9 The inability to consistently detect antibody to the 
98K DA in pigs exposed to low doses of virus raises the question of 
whether or not diagnostic tests using this antigen can be used to 
reliably detect PRV infections in the field. Although the present study 
/ 
j 
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only focused on the antibody response of subunit vaccinated pigs to a 
single protein it is possible that similar results may have occured if 
other non-vaccine diagnostic antigens were used. Consequently, it is 
essential that all potential non-vaccine diagnostic antigens should be 
thoroughly evaluated for efficacy in illlll\Uilized pigs that are exposed to 
low doses of virus before they are approved for use in PRV control 
programs. 
The preceding study also suggests thcit the ability of diagnostic 
tests to detect virus infection may be enhanced by sensitizing pigs with 
am::iunts of specific diagnostic antigens that do not induce detectable 
antibody. Sensitizing doses of specific diagnostic antigens =uld be 
in=rporated in the initial dose of subunit vaccine. Support for.this 
=ncept is based on the fact that vaccinated pigs responded to DA sooner 
than non-vaccinated pigs when tested by ELISA (Figure 2). This 
sensitization is believed to have been due to the presence of shared 
antigenic epitopes between the subunit vaccine and the DA. Earlier work 
in this laboratory demonstrated by crossed illlll\Uiloelectrophoresis that a 
degree of relatedness did exist between a component of the vaccine and 
DA. 7 It is also possible that the vaccine was contaminated with small 
am::iunts of DA. However, this explanation is not =nsidered likely 
because multiple vaccine doses did not induce detectable antibody to DA 
prior to virus exposure. 
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SECTION II. WESTERN IMMUNOBLOT ANALYSIS OF THE ANTIBODY RESPONSE OF 
SUBUNIT VACCINATED PIGS TO THE NUCLEOCAPSID PROTEINS OF 
PSEODORABIES VIRUS 
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SUM>1ARY 
The antibody response to pseudorabies virus (PRV) nucleocapsid 
proteins (NCP) was analyzed by western-immunoblot in 10 pigs immunized 
with PRV envelope glycoproteins following nasal Challenge with 102.3 PFU 
of virus. Antibody to five NCP with nolecular weights of 140K, 63K, 41K, 
34K, and 23K was initially detected in all vaccinates and six non-
vaccinated controls between days 14 and 21 post-challenge (p.c.). 
Antibody to 140K NCP was detected in eight of 10 subunit vaccinated pigs 
from 32 to 113 days p.c. Similarly, antibody to 63K NCP was detected in 
nine of 10 subunit vaccinated pigs from 32 to 113 days p.c. Nine of 10 
subunit vaccinated pigs produced antibody to 41K and 34K NCP from 21 to 
113 days and 32 to 113 days p.c. respectively. Antibody to 23K NCP was 
detected in eight of 10 subunit vaccinated pigs for 113 days p.c. One 
subunit vaccinated pig did not produce antibody to any NCP for a period 
longer than 32 days p.c. The antibody responses to two or nore 
individual NCP that included the 23K or 41K NCP were required to detect 
PRV infection in 9 of 10 subunit vaccinated pigs for 113 days p.c. These 
results indicate that NCP may be used as a non-vaccine diagnostic antigen 
in conjunction with PRV envelope glycoprotein based subunit vaccines. 
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INTRODUCTION 
Subunit vaccines may play an important role in PRV control programs 
because their use will permit the detection of wild type virus infection 
in vaccinates.lo The identification of virus infected vaccinates will 
depend on the ability to detect antibody to non-vaccine virus antigens. 
Since subunit vaccines will consist of one or more PRV envelope 
glycoproteins it is very likely that a non-vaccine diagnostic antigen 
that is COil!l?"tible with one subunit vaccine may represent an irnmunogen in 
another vaccine. As a result control programs will be more difficult to 
administrate because care will be required to insure that all pigs are 
vaccinated with the same vaccine to avoid false pcsitive· reactions. 
Diagnostic laboratories will also be required to test for antibody to 
more than one non-vaccine diagnostic-antigen. The use of a universal 
diagnostic antigen would facilitate the administration of control 
programs. Pseudorabies virus nucleocapsid proteins (NCP) are logical 
candidates for a universal diagnostic antigen because they have not been 
shown to play a role in protective immunity and will !!Ost likely not be a 
component of subunit vaccines. The following study was undertaken to 
determine if pigs immunized with PRV envelope glycoprotein respcnded to 
NCP following virus challenge. 
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MATERIAIS AND METHOOO 
Virus, Cells, and Medium 
Pseudorab~es virus (PRV) strain Be9 was used for viral antigen 
production and challenge virus. Madin Darby bovine kidney (MDBK) cells 
obtained from the National Veterinary Services Laboratory, Ames, IA were 
used for viral antigen production. ·Pig kidney (PK) la cells obtained 
from the Veterinary Medical Research Institute, Iowa State University, 
Ames, IA were used to propagate challenge virus. Growth medium consisted 
of Dulbecco's modified Eagle's medium supplemented with 10% fetal calf 
serum (GIBCO Laboratories, Grand Island, NY). 
PRV Subunit Vaccine 
Vaccine preparation has been previously described.B Essentially, 
viral glycoproteins extracted from solubilized PRV infected PK cell 
membranes were isolated by lectin affinity chromatography using Lens 
culnaris agglutinin covalently linked to agarose beads (E-Y Laboratories, 
San Mateo, CA). Bound glycoprotein was eluted with 2. 5% mannose in 
0.025M Tris/Tricine, pH 8.4 ana.· concentrated 10 fold by ultra-filtration 
through membrane with a 30,000 nolecular weight cut-off limit (Diaflo 
YM30 membrane, Amicon Corporation, Danvers, MA). The protein 
concentration of the column eluate was determined by a dye binding method 
described by Bradford. 2 Vaccine antigen was diluted and emulsified in an 
equal volume of Freund 's inconplete adjuvant. 
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PRV Nucleocapsid Antigen Preparation 
Pseudorabies virus nucleocapsids were isolated using a nodification 
of the method of Gibson and Roizrnan for isolation of herpes simplex type 
1 and 2 nucleocapsids.3 Cells from 10-850crn2 roller bottles were 
harvested 18 to 24 hours after infection and pelleted by low speed 
centrifugation at 1000 x g for 15 minutes. The cell pellet was washed 
three times in 500nM NaCl, 20nM Tris, pH 7.5 (TBS), resuspended in 20rnl 
of cell lysis (CL) buffer consisting of 1501!M NaCl, lOnM Tris, 21!M MgC12, 
pH 7.5, containing 1% Nonidet P-40 and incubated for 30 minutes at OOc. 
Infected cell nuclei were isolated by low speed centrifugation, washed 
twice in CL buffer and lysed in nuclei disruption (ND) buffer consisting 
of 5% sodium deoxycholate (IXJC) in CL buffer. The lysate was incubated 
at 37°C for 1 hour in the presence of 50ug/rnl deoxyribonuclease I (Sigma 
Chemical Company, St Louis, M:l) and clarified by low speed 
centrifugation. The clarified supernatant was layered onto 5 to 45% 
glycerol step gradients. Nucleocapsids were pelleted by centrifugation 
at 24,000 rpm for 90 minutes and resuspended in TBS. Resuspended 
nucleocapsids were adsorbed for 30 minutes at room temperature with Lens 
culnaris agglutinin covalently linked to agarose beads (E-Y Laboratories) 
to renove residual PRV glycoproteins. The nucleocapsid preparation was 
aliquoted and stored at -7o0 c. 
48 
Sodium Ileodecyl Sulfate-Polyacrylamide Electrophoresis (SDS-PAGE) 
Pseudorabies virus NCP and molecular weight markers were diluted in 
an equal volume of sanple preparation buffer consisting of 2% SDS, 4% B-
mercaptoethanol, 0.05% brom:JPhenol blue and 50% glycerol in 0.5M Tris 
buffer, pH 6.8, boiled for five minutes and separated under reducing 
conditions by standard SDS-PAGE methods. 4 Stacking and separating gels 
consisted of 4 and 10% acrylamide m:momer respectively, cross-linked with 
bis-acrylamide at a ratio of 30:0.8. All gels were electrophoresed at 25 
ml\. until the sanples reached the stacking gel/separating gel interface. 
Sanple separation was completed by electrophoresis at a constant current 
of 35 ml\. until the dye front had migrated 15 cm. The 15 cm migration 
limit was imposed on all separations to standardize protein migration 
patterns for later comparison. 
Electrophoretic Transfer of PRV Proteins 
Pseudorabies virus NCP and molecular weight markers were 
electrophoretically transferred to nitrocellulose immediately following 
SDS-PAGE. Proteins were transferred for 16 hours at 30 V followed by a 2 
hour finishing period at 100 V in transfer buffer consisting of 25rrM 
Tris, 192rrM Glycine, pH 8.3 and 20% v/v methanol. Following transfer, 
the nitrocellulose sheets were cut into 0.5 cm strips, air dried, and 
used immediately. Total NCP profiles were visualized by india ink 
staining as described by Hancock and Tsang.5 
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Western-Immunoblot Assay 
Nitrocellulose strips containing separated NCP were were blocked 
with 2.5% gelatin in TBS for two hours at 37°c and were washed for three 
5 minute cycles in TBS containing 0.05% Tween 20 (Tl'BS). Serums were 
diluted 1/100 in Tl'BS containing 1% gelatin, incubated with the 
nitrocellulose strips for 1 hour at room temperature, and washed as 
described above. Specific antigen-antibody reactions were visualized 
using a biotin-streptavidin detection system. Biotin labelled goat 
anti-porcine IgG (H+L) antibody (Kirkegaard & Perry Laboratories, 
Gaithersburg, MD) was used at a 1/2000 dilution followed by 
streptavidin-horseradish peroxidase conjugate (Kirkegaard & Perry 
Laboratories) at a 1/4000 dilution. All incubations were for one hour at 
room temperature with washing as described above. Enzyme substrate was 
prepared inunediately before use and consisted of 60ng of 4-chloro-1-
napthol in 20ml of ice cold methanol and 60ul of cold 30% hydrogen 
peroxide in lOOml of TBS. Color reactions were developed at room 
temperature in the dark for 40 minutes and stopped by two brief washes in 
deionized water. 
Serum Neutralization 
Serum neutralization (SN) titers were determined as previously 
d 'bed6 10 escri ' and are expressed as the reciprocal of log2• 
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Experimental Design 
Ten pigs were inoculated s.c. with one lOOug and two 50ug doses of 
vaccine antigen at three week intervals. Six pigs served as non-
vaccinated =ntrols. Vaccinates and =ntrols were separated 21 days 
after the third vaccine dose and nasally challenged with 102·3 PFU of PRV 
in two ml of naintenance medium. Serums were =llected on days O, 4, 7, 
10, 14, and 21 p.c. and assayed for antibody to NCP. Non-vaccinated 
=ntrols were killed at 21 days p.c. Challenged vaccinates were 
naintained through day 113 p.c. and the antibody response of these pigs 
to individual NCP was characterized by western-innnunoblot assay. 
Specific antibody responses to individual proteins were analyzed by the 
Chi-square test for independence. During this period SN titers of 
individual pigs continuously declined indicating the absence of 
spontaneous viral recrudescence which might influence the duration of the 
antibody response to NCP antigens. 
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RESULTS 
Detection of Antibody in Subunit Vaccinated Pigs to PRV Nucleocapsid 
Protein (NCP) by Western-Inmrunobl~t 
The antibody response of subunit vaccinated pigs as detected by 
western-inmrunoblot assay is illustrated in Figure 1. Antibody responses 
to a total of five NCP with molecular weights of 140K, 63K, 41K, 34K, and 
23K were studied. The molecular weight estimations of the NCP utilized 
in this study are in close agreement with species described in previous 
studies. 1•11 The antibody response to each of these proteins is 
summarized in Table 1. 
Table 1. The antibody response of 10 subunit vaccinated pigs to 
nucleocapsid protein (NCP) as detected by western-inmrunoblot assay 
Days tested post-challenge 
NCP 0 7 10 14 21 32 53 96 113 
140K oa 0 0 8 8 8 6 6 4 
63K 0 0 0 9 9 9 8 5 5 
41K 0 0 0 10 10 9 9 9 7 
34K 0 0 0 10 10 10 9 6 6 
23K 0 0 0 8 8 8 8 8 8 
~e total number of pigs with detectable antibody to nucleocapsid 
protein. 
Figure 1. Western-immunoblot detection of pre- and post-
challenge antibody responses of subunit vaccinated 
pigs to five pseudorabies virus (PRV) nucleocapsid 
proteins (140K, 63K, 41K, 34K and 23K). 
Lane MW= molecular weight markers 
Lane A= PRV subunit vaccinate, pre-challenge 
Lane B= PRV subunit vaccinate, 21 days post-challenge 
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No antibody to any PRV NCP was detected prior to virus challenge. 
Antibody to NCP was first detected on day 14 or 21 p.c. in both subunit 
vaccinated and non-vaccinated control pigs. Antibody to the 140K NCP was 
initially detected in eight of 10 pigs. It ceased to be detected after 
days 32 and 96 p.c. in two and two pigs respectively, but was detectable 
in four pigs through day 113 p.c. Similar results were observed with the 
63K NCP. Antibody was initially detected in nine of 10 pigs. It ceased 
to be detected after days 32 and 53 p.c. in one and two pigs 
respectively, but was detectable in six pigs through day 113 p.c. 
Antibody to 41K NCP was detected in all 10 subunit vaccinated pigs. 
Antibody to this protein ceased to be detected after days 21 and 96 p.c. 
in one and two pigs respectively, but was detected in seven pigs through 
day 113 p.c. Similarly, all subunit vaccinated pigs produced antibody to 
the 34K NC protein. Antibody to this protein ceased to be detected after · 
days 32 and 53 p.c. in one and three pigs respectively, but was 
detectable in six pigs through day 113 p.c. Antibody to the 23K NC 
protein was initially detected in eight of 10 pigs and remained 
detectable in all eight through day 113 p.c. One pig did not respond to 
any NC protein for a period longer than 32 days p.c. Chi-square analysis 
dem::instrated dependency in the antibody response to the 140K and 63K NCP. 
However, the analysis failed to dem::instrate either dependency or 
independency of the antibody response to other combinations of individual 
NCP. 
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DISCUSSION 
The following study was conducted to determine if virus infection 
induced by a low exposure dose could be detected in immunized pigs by 
testing for antibody to nucleocapsid proteins. Results of this study 
have shown that pigs will respond variably to five distinct NCP as 
revealed by the number of pigs with detectable antibody to specific NCP 
on day 113 p.c. (Table 1). At this time antibody to the 23K, 41K, 34K, 
63K and 140K was detected in 8, 7, 6, 5, and 4 pigs respectively 
suggesting that the 23K, 34K, and 41K NCP were the most immunogenic 
components of the preparation. Hcwever, the antibody response to any of 
these three antigens alone failed to detect virus infection in all pigs 
tested on day 113 p.c. This indicates that combinations of individual 
NCP may be required for the reliable long term detection of PRV infection 
induced by lciw exposure doses in subunit vaccinated pigs. Assuming that 
the antibody responses to the 23K, 34K, and 41K NCP are independent a 
combination of these three antigens would detect virus infection in 99.8 
and 97.6% of pigs at day 96 and 113 p.c. respectively. While these 
results appear promising additional testing with larger numbers of pigs 
are required to establish independency in the antibody response to 23K, 
34K, and 41K NCP. 
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SUMMARY AND CONCLUSIONS 
Pseudorabies virus (PRV) subunit vaccinated pigs will be exposed to 
virus doses approaching the mininrum infective dose under field 
conditions. This may result in PRV infections being suppressed before 
sufficient al!Dunts of non-vaccine diagnostic antigen are produced. 
Insufficient a11Dunts of diagnostic antigen would presumably induce low 
levels of specific antibody. Consequently, latent infections in these 
subunit vaccinated pigs may go undetected. In the preceding studies two 
diagnostic antigen preparations were evaluated with these concerns in 
mind. 
TWo experiments were conducted in the first study. In the first 
experiment the effect of subunit vaccine dose and virus exposure dose on 
the host antibody response to to a non-vaccine 98K early excreted PRV 
protein diagnostic antigen (DA) was studied in 18 pigs. TWo groups of' 
six pigs received high (200 ug total protein) and low (100 ug total 
protein) doses of subunit vaccine antigen. TWo groups of three pigs 
served as non-vaccinated controls. One group of pigs from each of the 
preceding categories was intranasally challenged with 102.7 or 106.0 PFU 
of virus. Antibody to DA was detected by ELISA and RIP three to seven 
days earlier in pigs exposed to 106•0 PFU. Vaccine dose did not affect 
DI\. antibody responses. 
In a related experiment, the frequency of latency induced by low PRV 
exposure doses and the ability of ELISA using DA to detect latent 
infections was studied in 10 subunit vaccinated pigs •. Following 
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intranasal challenge with 102.3 PFU of virus serum-virus neutralizing 
(SN) and DA antibody titers were monitored for 113 days post-challenge 
(p.c. ). The SN titers of individual pigs peaked between 14 and 21 days 
p.c. and steadily declined through day 113 p.c. indicating the absence of 
spontaneous viral recrudescence during the post-challenge period. 
Antibody to DA was detected in individual pigs for periods ranging from 
14 to 113 days p.c. Dexamethasone was used to induce virus recrudescence 
beginning on day 113 p.c. Eight of 10 pigs (80%) were considered to have 
been latently infected based on two log2 or greater increases in SN titer 
and/or recrudescent virus isolation. Antibody to DA was detected in six 
of eight latently infected pigs following dexamethasone treatment. No DA 
antibody was detected in the remaining two pigs (25%) despite increases 
in SN titer and virus recovery from one pig. 
The results of the two experiments in this first study indicate that 
the antibody response of subunit vaccinated pigs to DA is directly 
related to virus exposure dose. Furthermore, subunit vaccinated pigs can 
be latently infected with great frequency following exposure to virus 
doses approaching the minimum infective dose without developing 
persistent DA antibody. Both of these findings have important 
implications in future PRV control and eradication programs were the 
reliable identification of virus infected vaccinated pigs is critical. 
In the second study, a preliminary experiment was conducted to 
evaluate the performance of selected PRV nucleocapsid proteins (NCP) as 
non-vaccine diagnostic antigens.. The antibody responses of 10 subunit 
vaccinated and six non-vaccinated control pigs to five NCP were monitored 
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using westem-iilll!lllilOblot assay. The five NCP were not present in the 
lectin-<lerived PRV subunit vaccine preparations. All pigs were 
challenged with 102.3 PFU of virus. No antibody to NCP was detected 
prior to virus challenge. Antibody to NCP was first detected on day 14 
or 21 post-challenge (p.c.) in vaccinates and unvaccinated =ntrols. 
Vaccinated pigs =ntinued to be nvnitored for antibody to NCP through day 
113 p.c. All pigs responded to one or nvre NCP. The duration of 
antibody responses to individual NCP was variable. Antibody responses to 
two or nvre NCP were required to detect virus infection in nine of 10 
pigs for the entire 113 days p.c. One pig did not respond to any NCP 
antigen for a period longer than 32 days p.c. 
The results of this study indicate that NCP may be used as non-
vaccine diagnostic antigens in subunit vaccinated pigs. However, it is 
clear from this study that a single NCP =mponent will not be adequate. 
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